296P - Quality of life evaluation in patients with ovarian cancer on chemotherapy and its impact on patients’ perception of maintenance therapy (296P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Ovarian Cancer
Gynaecologic Malignancies
Presenter Shannen McDonald
Citation Annals of Oncology (2017) 28 (suppl_10): x86-x93. 10.1093/annonc/mdx663
Authors T. Le, B. Lauzon, J. Forget, S. McDonald
  • Gynecology, The Ottawa Hospital Regional Cancer Centre, K1H8L6 - Ottawa/CA

Abstract

Background

Ovarian cancer often present at an advanced stage with multiple recurrences. A number of targeted agents have been shown to be effective in prolonging progression-free survivals. We examined the quality of life of ovarian cancer patients on chemotherapy at time of diagnosis and recurrences and explore their attitude towards maintenance therapy.

Methods

All patients with ovarian/peritoneal cancer on chemotherapy were recruited. Standard socio demographics and treatment related variables were collected. FACT-O questionnaire was used to measure quality of life at baseline and after completion of each regimen. A separate questionnaire was also completed exploring patients willingness to continue with maintenance therapy and their expectation of benefit from the maintenance strategy. Patients were stratified into three groups: first diagnosis, first recurrence, and after two or more recurrences. ANOVA and paired T tests were used to examine differences between groups in each FACT-O subscale and total scores.

Results

A total of 128 patients were recruited. The median age was 64. 78% had stage 3/4 at diagnosis with 82% having serous histology. A quarter of patients were still working with most (78%) reported to be office workers. 61% of patients are married with good social support. ECOG performance status was 50%) for a prolongation of PFS of 6 months or less than those after initial diagnosis.

Conclusions

There was no significant overall QoL impact during chemotherapy in the adjuvant or palliative setting. Patients are very receptive to receiving effective maintenance therapies especially after experiencing disease recurrence.

Clinical trial identification

Legal entity responsible for the study

Dr Tien Le

Funding

Roche Pharmaceutical, Astra Zeneca

Disclosure

All authors have declared no conflicts of interest.